Yousif Capital Management LLC Has $2 Million Stock Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Yousif Capital Management LLC reduced its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 8.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 67,545 shares of the company's stock after selling 6,396 shares during the quarter. Yousif Capital Management LLC's holdings in Hims & Hers Health were worth $1,996,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Blume Capital Management Inc. raised its stake in shares of Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 600 shares in the last quarter. UMB Bank n.a. grew its holdings in shares of Hims & Hers Health by 247.5% during the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock valued at $39,000 after purchasing an additional 933 shares during the last quarter. Smartleaf Asset Management LLC increased its holdings in Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after purchasing an additional 1,413 shares in the last quarter. Summit Securities Group LLC bought a new stake in shares of Hims & Hers Health in the fourth quarter worth $38,000. Finally, US Bancorp DE raised its holdings in Hims & Hers Health by 346.7% during the 4th quarter. US Bancorp DE now owns 1,943 shares of the company's stock worth $47,000 after purchasing an additional 1,508 shares during the last quarter. Institutional investors own 63.52% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on HIMS shares. Leerink Partners boosted their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research report on Tuesday, February 25th. Bank of America upped their target price on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a research report on Tuesday, April 29th. Canaccord Genuity Group upped their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Truist Financial cut their target price on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a report on Thursday, April 10th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $38.00.

Insider Buying and Selling

In related news, CFO Oluyemi Okupe sold 11,581 shares of the stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $60.22, for a total transaction of $697,407.82. Following the completion of the transaction, the chief financial officer now directly owns 113,816 shares of the company's stock, valued at approximately $6,853,999.52. This represents a 9.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Michael Chi sold 5,600 shares of the firm's stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $57.00, for a total value of $319,200.00. Following the transaction, the insider now owns 256,380 shares of the company's stock, valued at $14,613,660. This represents a 2.14% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 499,940 shares of company stock valued at $21,478,932. Corporate insiders own 13.71% of the company's stock.

Hims & Hers Health Trading Down 3.2%

HIMS opened at $55.33 on Monday. Hims & Hers Health, Inc. has a 12-month low of $13.47 and a 12-month high of $72.98. The company has a market cap of $12.38 billion, a price-to-earnings ratio of 125.75 and a beta of 2.09. The company's 50 day moving average is $45.09 and its 200 day moving average is $38.26.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $586.01 million during the quarter, compared to analyst estimates of $535.21 million. During the same period in the prior year, the business posted $0.05 EPS. Hims & Hers Health's revenue was up 110.7% on a year-over-year basis. As a group, analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.